US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.77 against a street estimate of 1.08 — a beat of 63.9%.
Analysts rate Bausch Health Companies Inc a hold (0 buy, 7 hold, 0 sell out of 7) with an average price target of $8.00.
CONFIDENT Bausch Health delivered strong Q3 growth, record adjusted EBITDA, and debt reduction, raising 2026 guidance despite expected Q4 Xifaxan headwinds and Solta regional softness. Q3 FY26 International growth was broad-based; Solta China grew strongly, while consumer confidence, competitors and North American execution remained watch points. Analysts focused on corporate structure, Xifaxan’s 2027 pricing and litigation, Phase III timing, and Solta’s regional demand. Management highlighted optionality, quantified the Xifaxan impact, and described Solta softness as market and execution-related. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Paulson & Company Inc | 19.59% |
| Goldentree Asset Management LP | 9.27% |
| Royal Bank of Canada | 2.90% |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2.14% |
| Vanguard Capital Management, LLC | 2.00% |
| The Goldman Sachs Group Inc | 1.66% |
| MFN Partners Management, LP | 1.60% |
| SG Americas Securities, LLC | 1.48% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $2,941 million, up from $2,681 million in the third quarter of 2025. Product sales were $2,912 mill | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 consolidated revenue was $2.94 billion, up 10% reported and 8% organically versus $2.68 billion in the prior-ye | 2026-10-28 |
| Quarterly report · Q2 2026 BAUSCH HEALTH COMPANIES INC. - Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months ended June 30, 2026): $5,376 million ($5,325 mil | 2026-07-30 |
| Results announced · Q3 2026 BAUSCH HEALTH Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total Consolidated Revenues: $2.85 billion in Q2 2026, up 13% reported / 11% organic vs. Q2 | 2026-07-29 |
| Board / officer change · Q2 2026 BAUSCH HEALTH COMPANIES INC. — FORM 8-K SUMMARY Filing Date: June 26, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Board member resignation: Michael Go | 2026-07-01 |
| Shareholder vote results · Q2 2026 BAUSCH HEALTH COMPANIES INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting Date: May 19, 2026 • Company: Bausch Health Companies Inc., | 2026-05-19 |
| Quarterly report · Q1 2026 BAUSCH HEALTH COMPANIES INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Quarterly Revenue: $2,524 million (Q1 2026) vs. $2,259 million (Q1 2025) — in | 2026-04-30 |
| Results announced · Q2 2026 BAUSCH HEALTH Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total Consolidated Revenues: $2.52 billion, up 12% reported basis, up 7% organic basis vs. | 2026-04-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Reaffirms full year 2025 guidance at higher end of range Bausch Health Companies announced it will present at the J.P. Morgan Healthcare Conference on January 14, 2026, where management will provide strategic and business updates to investors. Mos | 2026-01-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bausch Health Companies Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.